Fecal Microbiota Transplantation (FMT) Market Forecast To Reach $1.27 Billion By 2030: Key Trends Explained

Fecal Microbiota Transplantation (FMT) Market Report

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Fecal Microbiota Transplantation (FMT) Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?

The fecal microbiota transplantation (fmt) market has experienced significant growth in recent years. It is projected to expand from $0.91 billion in 2025 to $0.98 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.1%. This historical growth can be primarily attributed to the growing recognition of the gut microbiome’s role in disease, the documented success of fmt in recurrent cdi cases, the expansion of hospital-based fmt programs, the provision of early regulatory guidance on microbiome therapies, and the increased availability of stool banks.

The fecal microbiota transplantation (fmt) market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $1.27 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.8%. Key factors driving this growth during the forecast period include intensified research into microbiome-derived therapies, a heightened need for standardized fmt products, the broadening of treatment applications beyond digestive disorders, increasing capital flowing into microbiome biotechnology, and advancements in oral administration methods. Significant trends emerging in the forecast timeframe encompass a greater emphasis on standardizing donor screening procedures, increased uptake of cryopreserved fmt options, wider clinical adoption beyond cdi treatment, the proliferation of capsule-based delivery methods, and an amplified focus on microbiome analytics.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=36885286&type=smp&name=Fecal%20Microbiota%20Transplantation%20%28FMT%29%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Fecal Microbiota Transplantation (FMT) Market Opportunity Drivers: What’s Unlocking New Revenue Potential?

The increasing occurrence of gastrointestinal conditions is projected to boost the expansion of the fecal microbiota transplantation (FMT) market in the future. Gastrointestinal (GI) disorders encompass diverse medical issues impacting the gastrointestinal tract, comprising organs such as the esophagus, stomach, small intestine, large intestine (colon), rectum, and anus. The surge in gastrointestinal ailments stems from elevated stress levels, inactive lifestyles, and greater intake of processed foods. Fecal microbiota transplantation finds application in gastrointestinal disorders for re-establishing beneficial gut bacteria, especially in managing recurring Clostridioides difficile infections. For example, data from Crohn’s and Colitis Canada, a non-profit organization based in Canada, indicated a rapid increase in the number of individuals in Canada suffering from IBD, rising from 322,600 in 2023 (representing 0.8% of the population) to an anticipated 470,000 by 2035 (or 1.1% of the population). In 2023, 11,000 people will receive a diagnosis (equating to 1 every 48 minutes), with this figure expected to climb to 14,000 by 2035 (meaning 1 every 38 minutes). Consequently, the growing occurrence of gastrointestinal disorders serves as a significant impetus for the expansion of the fecal microbiota transplantation (FMT) market.

Fecal Microbiota Transplantation (FMT) Market Segment Trends And Revenue Contributors

The fecal microbiota transplantation (fmt) market covered in this report is segmented –

1) By Type: Fermentation, Fresh, Cryopreservation

2) By Donor Type: Stool-Derived, Fecal-Derived, Whole-Microbiome Derived

3) By Indication: Clostridioides Difficile Infection, Inflammatory Bowel Disease, Metabolic Syndrome, Other Indications

4) By Administration Route: Oral, Rectal, Nasogastric, Colon Capsule

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Fermentation: Fermented FMT Products, Fermented Capsules, Fermented Liquids, In-House Fermentation Techniques

2) By Fresh: Fresh Stool Samples, Fresh FMT Capsules, Fresh FMT Solutions for In-Hospital Use, Freshly Prepared FMT for Outpatient Use

3) By Cryopreservation: Cryopreserved Stool Samples, Cryopreserved FMT Capsules, Cryopreserved Liquid FMT, Long-Term Storage Solutions for Cryopreserved FMT

Fecal Microbiota Transplantation (FMT) Market Innovation Trends: What Developments Are Reshaping The Industry?

Major companies operating in the fecal microbiota transplantation (FMT) market are focusing on incorporating standardized microbiota-based therapies, such as fecal microbiota spores, live-brpk, to enhance safety, patient compliance, treatment consistency, and scalability. Fecal microbiota spores, live-brpk are highly processed donor-derived microbial spores manufactured under strict screening and purification procedures to restore healthy gut microbiota with controlled dosing and reduced infection risk. For instance, in April 2023, Seres Therapeutics, a US-based microbiome therapeutics company, received FDA approval for VOWST, a fecal microbiota spores, live-brpk therapy designed to prevent recurrence of Clostridioides difficile infection in adults, featuring oral capsule delivery, defined microbial spore composition, and rigorous pathogen-screening protocols. VOWST improves treatment convenience, safety, and commercial scalability in the FMT sector.

Fecal Microbiota Transplantation (FMT) Market Competitive Landscape: Which Companies Lead The Industry?

Major companies operating in the fecal microbiota transplantation (fmt) market are Ferring Pharmaceuticals, Johns Hopkins Medicine, Seres Therapeutics, Taconic Biosciences, Enterome, Rebiotix Inc, Finch Therapeutics Group Inc, Locus Biosciences, Yeda Research and Development Co. Ltd, Microbiotica Limited, CosmosID Inc, AOBiome, Synthetic Biologics Inc., Osel Inc., OpenBiome, Asia Microbiota Bank, Taymount Clinic, MicroBiome Therapeutics LLC, MaaT Pharma SA, Kallyope

View The Full Fecal Microbiota Transplantation (FMT) Market Report:

https://thebusinessresearchcompany.com/report/fecal-microbiota-transplantation-fmt-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Fecal Microbiota Transplantation (FMT) Market Regional Split: Which Areas Are Fueling Growth?

North America was the largest region in the fecal microbiota transplantation (FMT) market in 2025. The regions covered in the fecal microbiota transplantation (fmt) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model